In a post-hoc analysis, researchers assessed the effects of lenvatinib compared with sorafenib on health-related quality of life in patients with hepatocellular carcinoma.
Researchers aimed to validate use of the NCYA score and its incorporation of AFP-R in the selection of patients for liver transplant due to HCC recurrence.
Researchers compared the cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma.
The approval was based on data from the LEGACY study, a single-arm, retrospective trial that evaluated treatment with TheraSphere Y90 glass microspheres in 162 patients with unresectable hepatocellular carcinoma.
Bernstam et al presented findings from an expansion cohort of a phase 1 trial testing the bispecific HER2-targeted antibody zanidatamab in patients with HER2-overexpressing biliary tract cancer.
The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life.
Intolerance to treatment with direct acting antiviral treatment was found to be associated with older age and advanced liver disease in patients with hepatocellular carcinoma.
Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.
